Diroximel fumarate is an effective treatment for young adults with multiple sclerosis, according to study results presented at the 2022 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) held from June 1-4, in National Harbor, Maryland.
Compared with dimethyl fumarate, diroximel fumarate has superior gastrointestinal (GI) tolerability and decreased rates of discontinuation associated with GI adverse events (AE), the researchers said. Yet, outcomes for young adult patients treated with diroximel fumarate have not previously been reported. In this study, researchers assessed diroximel fumarate outcomes among adults aged 18 to 25 years who participated in the open-label EVOLVE-MS-1 study (ClinicalTrials.gov identifier: NCT02634307).
Patients in the EVOLVE-MS-1 study had either been newly diagnosed with MS or had completed the randomized, double-blind, 5-week phase 3 EVOLVE-MS-2 study (ClinicalTrials.gov identifier: NCT03093324) of diroximel fumarate or dimethyl fumarate.